Rat models of hypertension, cardiac hypertrophy and failure

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 89-105

  Doggrell, Sheila A ^a   Brown, Lindsay ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NONE

Author keywords

Cardiac failure; Cardiac hypertrophy; Hypertension; Rat models

Indexed keywords

ISOPRENALINE; MINERALOCORTICOID; MONOCROTALINE; NITRIC OXIDE SYNTHASE; NORADRENALIN;

ALCOHOLIC CARDIOMYOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTIFICIAL EMBOLISM; CARDIOVASCULAR RISK; CORONARY ARTERY LIGATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY ARTERY STENOSIS; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RENIN ANGIOTENSIN DISORDER; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HEART FAILURE, CONGESTIVE; HYPERTENSION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, MUTANT STRAINS;

EID: 0032127809     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00076-5     Document Type: Review

References (194)

1. [1] Kannel WB. Hypertension as a risk for cardiac events - epidemiological results of long-term studies. J Cardiovasc Pharmacol 1993;21(Suppl 2):S27-S37.
2. [2] Weindruch R. Animal models. In: Masoro EJ, editors. Handbook of physiology, section 11: Aging. New York, Oxford: Oxford University Press, 1995:37-52.
3. [3] Editorial. The role of animal experimentation in cardiovascular therapeutic discovery. Cardiovasc Res 1994;28:1102-1118.
4. [4] Hanes DS, Wier MR, Sowers JR. Gender considerations in hypertension pathophysiology and treatment. Am J Med 1996;101:10S-21S.
5. [5] Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses health study. New Engl J Med 1991;325:756-762.
6. [6] Bohr DF, Dominiczak AF, Webb RC. Pathophysiology of the vasculature in hypertension. Hypertension 1991;18(Suppl 111):S69-S75.
7. [7] Dzau VJ, Gibbons GH, Kobilka BK, Lawn RM, Pratt RE. Genetic models of human vascular disease. Circulation 1995;91:521-531.
8. [8] de Jong W, editor. Experimental and genetic models of hypertension. In: Birkenhger W, Reid JL, editors. Handbook of hypertension, vol 4. Amsterdam, New York, Oxford: Elsevier, 1984:1-549.
9. [9] Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Japan Circ J 1963;27:282-293.
10. [10] Kurtz TW, Morris RC. Biological variation in WKY rats: implications for research with the spontaneously hypertensive rat. Hypertension 1987;10:127-131.
11. [11] Adams MA, Bobik A, Korner PI. Differential development of vascular and cardiac hypertrophy in genetic hypertension. Hypertension 1989;14:191-201.
12. [12] McGuire PG, Tweitmeyer TA. Aortic endothelial functions in developing hypertension. Hypertension 1985;7:483-490.
13. [13] Iams SG, Wexler BC. Inhibition of the development of spontaneous hypertension in SH rats by gonadectomy or estradiol. J Lab Clin Med 1979;10:608-616.
14. [14] Smith TL, Hutchins PM. Central hemodynamics in the developmental stages of spontaneous hypertension in the anaesthetized rat. Hypertension 1979;1:508-517.
15. [15] Takata Y, Kato H. Adrenoceptors in SHR: alterations in binding characteristics and intracellular signal transduction pathways. Life Sci 1996;58:91-106.
16. [16] Lund-Johansen P. Hemodynamic effects of felodipine in hypertension: a review. J Cardiovasc Pharmacol 1990;15(suppl 4):S34-39.
17. [17] Lindpaintner K, Kreutz R, Ganten D. Genetic variation in hypertensive and 'control' strains. What are we controlling for anyway?. Hypertension 1992;19:428-430.
18. [18] Aitman TJ, Gotoda T, Evans AL, et al. Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet 1997;16:197-201.
19. [19] Kovcs P, Voigt B, Klöting I. Novel quantitative trait loci for blood pressure and related traits on rat chromosomes 1,10, and 18. Biochem Biophys Res Commun 1997;235:343-348.
20. [20] Dukhanina OI, Dene H, Deng AY, Choi CR, Hoebee B, Rapp JP. Linkage map and congenic strains to localize blood pressure QTL on rat chromosome 10. Mamm Genome 1997;8:229-235.
21. [21] Kren V, Pravenec M, Lu S, et al. Genetic isolation of a region of chromosome 8 that exerts major effects on blood pressure and cardiac mass in the spontaneously hypertensive rat. J Clin Invest 1997;99:577-581.
22. [22] Folkow B. Early structural changes in hypertension: pathophysiology and clinical consequences. J Cardiovasc Pharmacol 1993;22(Suppl 1):S1-S6.
23. [23] Kauser K, Rubanyi GM. Gender differences in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension 1995;25:517-524.
24. [24] Nigro D, Fortes ZB, Scivoletto R, Barbeiro HV, Carvalho MH. Sex-related differences in the response of spontaneously hypertensive rats to angiotensin-converting enzyme inhibition. Endothelium 1997;5:63-71.
25. [25] Folkow B, Svanborg A. Physiology of cardiovascular aging. Physiol Rev 1993;73:725-758.
26. [26] St Lezin E, Simonet L, Pravenec M, Kurtz TW. Hypertensive strains and normotensive 'control' strains. How closely are they related?. Hypertension 1992;19:419-424.
27. [27] Johnson ML, Ely DL, Turner ME. Genetic divergence between the Wistar-Kyoto rat and the Spontaneously Hypertensive Rat. Hypertension 1992;19:425-427.
28. [28] Louis WJ, Howes LG. Genealogy of the spontaneously hypertensive rat and Wistar-Kyoto rat strains: Implications for studies of inherited hypertension. J Cardiovasc Pharmacol 1990;16(Suppl 7):S1-S5.
29. [29] Clineschmidt BE, Geller RG, Govier WG, Sjoerdsma A. Reactivity to norepinephrine and nature of the alpha adrenergic receptor in vascular smooth muscle of a genetically hypertensive rat. Eur J Pharmacol 1970;10:45-50.
30. [30] Ledingham JM, Laverty R. Nitric oxide synthase inhibition with N omega-nitro-L-arginine methyl ester affects blood pressure and cardiovascular structure in the genetically hypertensive rat strain. Clin Exp Pharmacol Physiol 1997;24:433-435.
31. [31] Bianchi G, Ferrari P. A genetic approach to the pathogenesis of primary hypertension and to its treatment. Clin Exp Pharmacol Physiol 1995;22:S399-S405.
32. [32] Heller J, Hellerova S, Dobesova Z, Kunes J, Zicha J. The Prague Hypertensive Rat: a new model of genetic hypertension. Clin Exp Hypertens 1993;15:807-818.
33. [33] Sassard J, Vincent M, Orea V, Privat P, Bataillard A. Genetics of blood pressure and associated phenotypes in the Lyon rat. Clin Exp Hypertens 1997;19:567-575.
34. [34] Crespo MJ, Escobales N, Rodriguez-Sargent C. Endothelial dysfunction in the San Juan hypertensive rat: possible role of the nitric oxide synthase. J Cardiovasc Pharmacol 1996;27:802-808.
35. [35] Bannister R. In: Brain and Bannister's clinical neurology, 7th ed., Oxford: Oxford Medical Publications, 1992:237-282.
36. [36] Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat. Circ Res 1974;34-35(suppl I):I143-153.
37. [37] Vacher E, Richer C, Fornes P, Clozel J-P, Guidicelli J-F. Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996;27:686-694.
38. [38] Stasch J-P, Hirth-Dietrich C, Frobel K, Wegner M. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1995;8:1128-1134.
39. 1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 1996;118:549-556.
40. [40] Nagura J, Hui C, Yamamoto M, et al. Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995;22(Suppl 1):S363-S365.
41. [41] de Champlain J, Krakoff LR, Axelrod J. Catecholamine metabolism in experimental hypertension in the rat. Circ Res 1967;20:136-145.
42. [42] de Champlain J, Mueller RA, Axelrod J. Turnover and synthesis of norepinephrine in experimental hypertension in rats. Circ Res 1969;25:285-291.
43. [43] Schenk J, McNeill JH. The pathogenesis of DOCA-salt hypertension. J Pharmacol Toxicol Methods 1992;27:161-170.
44. [44] Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension 1997;29:494-499.
45. [45] Hilditch A, Hunt AA, Gardner CJ, et al. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist. Br J Pharmacol 1994;111:137-144.
46. [46] Li JS, Schurch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 1996;9:803-811.
47. [47] Garwitz ET, Jones AW. Aldosterone infusion into the rat and dose-dependent changes in blood pressure and arterial ionic transport. Hypertension 1982;4:374-381.
48. [48] White PC. Inherited forms of mineralocorticocoid hypertension. Hypertension 1996;28:927-936.
49. [49] McMahon EG, Paul RJ. Calcium sensitivity of isometric force in intact and chemically skinned aortas during the development of aldosterone-salt hypertension in the rat. Circ Res 1985;56:427-435.
50. [50] Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Progr Cardiovasc Dis 1995;38:87-104.
51. [51] Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994;31:131-143.
52. [52] Deng AY, Rapp JP. Locus for the inducible, but not a constitutive, nitric oxide synthase cosegregates with blood pressure in the Dahl salt-sensitive rat. J Clin Invest 1995;95:2170-2177.
53. [53] Bonnardeaux A, Nadaud S, Charru A, Jeunemaitre X, Corvol P, Soubrier F. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation 1995;91:96-102.
54. [54] Hropot M, Grötsch H, Klaus E, et al. Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn-Schmiedeberg's Arch Pharmacol 1994;350:646-652.
55. [55] Richer C, Boulanger H, Es-Slami S, Giudicelli J-F. Lack of beneficial effects of the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats. Br J Pharmacol 1996;119:1642-1648.
56. [56] Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
57. [57] Hsueh WA. Effect of the renin-angiotensin system in the vascular disease of Type II diabetes mellitus. Am J Med 1992;92:13S-19S.
58. [58] Anonymous . Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28:1039-1057.
59. [59] van Zwieten PA, Kam KL, Pijl AJ, Hendriks MGC, Beenen OHM, Pfaffendorf M. Hypertensive diabetic rats in pharmacological studies. Pharmacol Res 1996;33:95-105.
60. 1-receptor blockade. Am J Hypertens 1996;9:895-901.
61. [61] Rosenthal T, Erlich Y, Rosenmann E, Cohen A. Effects of enalapril, losartan and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Hypertension 1997;29:1260-1264.
62. [62] Zucker LM, Zucker TF. Fatty: a new mutation in the rat. J Hered 1961;52:275-278.
63. [63] Math D. Dyslipidemia and diabetes: animal models. Diabetes Metab 1995;21:106-111.
64. [64] Kasiske BL, O'Donnell MP, Keane WF. The Zucker model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992;19(suppI):I110-I115.
65. [65] Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension 1997;29:725-728.
66. [66] Paulson DJ, Tahiliani AG. Cardiovascular abnormalities associated with human and rodent obesity. Life Sci 1992;51:1557-1569.
67. [67] Russell JC, Amy RM. Myocardial and vascular lesions in the La/N-corpulent rat. Can J Physiol Pharmacol 1986;64:1272-1280.
68. [68] Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. 1. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-379.
69. [69] Robertson JIS. Renin and the pathology of renovascular hypertension. In: Robertson JIS, Nicholls MG, editors. The renin-angiotensin system, Mosby, 1993:55.1-55.34.
70. [70] Weber KT, Janicki JS, Rick R, Capasso J, Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990;65:1G-7G.
71. [71] Brown L, Sernia C. Angiotensin receptors in cardiovascular disease. Clin Exp Pharmacol Physiol 1994;21:811-881.
72. [72] Dussaule J-C, Mitchel J-B, Auzan C, Schwartz K, Corvol P, Menard J. Effect of antihypertensive treatment on the left ventricular isomyosin profile in one clip, two kidney hypertensive rats. J Pharmacol Exp Ther 1986;236:512-518.
73. [73] Raine AEG, Seymour A-ML, Roberts AFC, Radda GK, Ledingham JGG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993;92:2934-2940.
74. [74] Suzuki H, Schaefer L, Ling H, et al. Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995;15:129-136.
75. [75] Amann K, Wiest G, Zimmer G, Bretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992;42:1079-1085.
76. [76] Villa E, Rábano A, Cazes M, Cloarec A, Ruilope LM, Garciá-Robles R. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997;10:275-281.
77. [77] Black MJ, Campbell JH, Campbell GR. Differential effect of renal wrap hypertension on aortic smooth muscle polyploidy in the rat and rabbit. Clin Exp Pharmacol Physiol 1994;21:249-251.
78. [78] Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64:1041-1050.
79. [79] Riedel M, Hall RJC, Haworth SG. Disorders of the pulmonary circulation. In: Julian DG, Camm AJ, Fox KM, Hall RTC, Poole-Wilson PA, editors. Diseases of the heart, 2nd ed. London: Saunders, 1996:1236-1280.
80. [80] Grossman W. Pulmonary hypertension. In: Braunwald, E, editor. Heart disease: a textbook of cardiovascular medicine, 4th ed. Philadelphia: Saunders, 1992:790-816.
81. [81] Rabinovitch M. Pulmonary hypertension: updating a mysterious disease. Cardiovasc Res 1997;34:268-272.
82. [82] Werchan PM, Summer WR, Gerdes AM, McDonough KH. Right ventricular performance after monocrotaline-induced pulmonary hypertension. Am J Physiol 1989;256:H1328-H1336.
83. [83] Wanstall JC, O'Donnell SR. Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur J Pharmacol 1990;176:159-168.
84. [84] Pelà G, Missale C, Raddino R, Condorelli E, Spano PF, Visioli O. β1- and β2-receptors are differentially desensitized in an experimental model of heart failure. J Cardiovasc Pharmacol 1990;16:839-846.
85. [85] Vescovo G, Jones SM, Harding SE, Poole-Wilson PA. Isoproterenol sensitivity of isolated cardiac myocytes from rats with monocrotaline-induced right-sided hypertrophy and heart failure. J Mol Cell Cardiol 1989;21:1047-1061.
86. [86] Brown L, Miller J, Dagger A, Sernia C. Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. J Cardiovasc Pharmacol 1998;31:108-115.
87. [87] Bristow MR, Minobe W, Rasmussen R, et al. beta-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803-815.
88. [88] Ceconi C, Condorelli E, Quinzanini M, Rodella A, Ferrari R, Harris P. Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive heart failure. Cardiovasc Res 1989;23:674-682.
89. [89] DiCarlo VS, Chen S-J, Meng QC, et al. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 1995;269:L690-L697.
90. [90] Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol 1979;236:H818-H827.
91. [91] Block ER, Herrera H, Couch M. Hypoxia inhibits L-arginine uptake by pulmonary artery endothelial cells. Am J Physiol 1995;269:L574-L580.
92. [92] Xue C, Johns RA. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodelling in the hypoxic rat. Hypertension 1996;28:743-753.
93. [93] Pelouch V, Kolr F, Ostadál B, Milerova B, Cihak R, Widimsky J. Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Cardiovasc Drugs Ther 1997;11:177-185.
94. [94] Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269:H1186-H1194.
95. [95] Kolár F, Ostadál B. Right ventricular function in rats with hypoxic pulmonary hypertension. Pflugers Arch/Eur J Physiol 1991;419:121-126.
96. [96] Heath D. The rat is a poor animal model for the study of human pulmonary hypertension. Cardioscience 1992;3:1-6.
97. [97] Shapiro LM, Sugden PH, Left ventricular hypertrophy. In: Julian DG, Camm AJ, Fox KM, Hall RTC, Poole-Wilson PA, editors. Diseases of the heart. 2nd ed. London: Saunders, 1996.
98. [98] Braunwald E, Clinical manifestations of heart failure. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine, 3rd ed. Philadelphia: Saunders, 1988:471-484.
99. [99] Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:950-957.
100. [100] Katz AM. Heart failure. In: Physiology of the heart, 2nd ed. New York: Raven Press, 1992:638-668.
101. [101] Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. New Engl J Med 1996;335:1182-1189.
102. [102] Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. New Engl J Med 1997;336:1131-1141.
103. [103] Nishigaki K, Minatoguchi S, Seishima M, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis in patients with chronic congestive heart failure. J Am Coll Cardiol 1997;29:1214-1220.
104. [104] Smith HJ, Nuttall A. Experimental models of heart failure. Cardiovasc Res 1985;19:181-186.
105. [105] Einstein R, Abdul-Hussein N. Animal models of heart failure for pharmacological studies. Clin Exp Pharmacol Physiol 1995;22:864-868.
106. [106] Elsner D, Riegger GAJ. Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol 1995;10:253-259.
107. [107] Mitchell GF, Pfeffer JM, Pfeffer MA. The transition to failure in the spontaneously hypertensive rat. Am J Hypertens 1997;10:120S-126S.
108. [108] Nand V, Doggrell SA, Barnett CW Effects of veratridine on the action potentials and contractility of right and left ventricles from normo-and hypertensive rats. Clin Expt Pharmacol Physiol 1997;24:570-576.
109. [109] Brooksby P, Levi AJ, Jones JV. The electophysiological characteristics of hypertrophied ventricular myocytes from the spontaneously hypertensive rat. J Hypertension 1993;11:611-622.
110. [110] Hamet P, Richard L, Dam T-V, et al. Apoptosis in target organs in hypertension. Hypertension 1995;26:642-648.
111. [111] Brooksby P, Levi AJ, Jones JV. Contractile properties of ventricular myocytes isolated from the spontaneously hypertensive rat. J Hypertens 1992;10:521-527.
112. [112] Anversa P, Capasso JM, Olivetti G, Sonnenblick EH. Cellular basis of ventricular remodelling in hypertensive cardiomyopathy. Am J Hypertension 1992;5:758-770.
113. [113] Li P, Zhang X, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P. Myocyte loss and left ventricular failure characterise the long term effects of coronary artery narrowing or renal hypertension in rats. Cardiovasc Res 1993;27:1066-1075.
114. [114] Anversa P, Li P, Malhotra A, Zhang X, Herman MV, Capasso JM. Effects of hypertension and coronary constriction on cardiac function, morphology, and contractile proteins in rats. Am J Physiol 1993;265:H713-H724.
115. [115] Cutilletta AF, Dowell RJ, Rudnik M, Arcella RA, Zak R. Regression of myocardial hypertrophy 1. Experimental model, changes in heart weight, nucleic acids and collagen. J Mol Cell Cardiol 1975;7:767-780.
116. [116] Mercadier J-J, Lompre A-M, Wisnewsky C, et al. Myosin isoenzymic changes in several models of rat cardiac hypertrophy. Circ Res 1981;49:525-552.
117. [117] Le Liévre LG, Maixent JM, Lorents P, Movas C, Charlemagne D, Swynghedauw B. Prolonged responsiveness to ouabain in hypertrophied rat heart: physiological and biochemical evidence. Am J Physiol 1986;250:H923-H931.
118. [118] Chevalier B, Mansier P, Callens-El Amranis F, Swynghedauw B. beta-Adrenergic system is modified in compensatory pressure cardiac overload in rats: Physiological and biochemical evidence. J Cardiovasc Pharmacol 1989;13:412-420.
119. [119] Mertens M, Mathy M-J, Pfaffendorf M, van Zwieten PA. Depressed inotropic response to beta-adrenoceptor agonists in the presence of advanced cardiac hypertrophy in hearts from rats with induced aortic stenosis and spontaneously hypertensive rat. J Hypertens 1992;10:1361-1368.
120. [120] Toffolo RL, Ianuzzo CD. Myofibrillar adaptations during cardiac hypertrophy. Mol Cell Biochem 1994;131:141-149.
121. [121] Teiger E, Dam T-V, Richard L, et al. Apoptosis in pressure-overload induced heart hypertrophy in the rat. J Clin Invest 1996;97:2891-2892.
122. [122] Foster KA, Hock CE, Reibel DK. Altered responsiveness of hypertrophied rat hearts to alpha-and beta-adrenergic stimulation. J Mol Cell Cardiol 1991;23:91-101.
123. 2+ ATPase in congestive heart failure due to diabetes. Angiology 1993;44:769-775.
124. [124] Ito N, Nitta Y, Ohtani H, Ooshima A, Isoyama S. Remodelling of microvessels by coronary hypertension or cardiac hypertrophy in rats. J Mol Cell Cardiol 1994;26:49-59.
125. [125] Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984;311:819-823.
126. [126] Brodde O-E. beta1- and beta2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203-242.
127. [127] Brown L, Sernia C, Newling R, Fletcher P. Cardiac responses after norepinephrine-induced ventricular hypertrophy in rats. J Cardiovasc Pharmacol 1992;20:316-323.
128. [128] Mende U, Eschenhagen T, Geertz B, et al. Isoprenaline-increased increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 1992;345:44-50.
129. [129] Sarsero D, Molenaar P. Effects of chronic infusion of (-)-isoprenaline on rat cardiac muscarinic (M2)-cholinoceptors and beta 1-and beta 2-adrenoceptors. J Auton Pharmacol 1995;15:239-255.
130. [130] Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodelling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994;75:105-113.
131. [131] Rosenbaum JS, Billingham ME, Ginsburg R, Tsujimoto G, Lurie KG, Hoffman BB. Cardiomyopathy in a rat model of pheochromocytoma. Morphological and functional alterations. Am J Cardiovasc Path 1988;1:389-399.
132. [132] Paul M, Wagner J, Hoffmann S, Urata H, Ganten D. Transgenic rats: new experimental models for the study of candidate genes in hypertension research. Ann Rev Physiol 1994;56:811-829.
133. [133] Lee AE, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996;270:E919-E929.
134. [134] Böhm M, Moll M, Schmid B, et al. beta-Adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension 1996;24:653-662.
135. [135] Brosnihan KB, Moriguchi A, Nakamoto H, Dean RH, Ganten D, Ferrario CM. Estrogen augments the contribution of nitric oxide to blood pressure regulation in transgenic hypertensive rats expressing the mouse Ren-2 gene. Am J Hypertens 1994;7:575-582.
136. [136] Li P, Ferrario CM, Ganten D, Brosnihan KB. Chronic estrogen treatment in female transgenic (mRen2)27 hypertensive rats augments endothelium-derived nitric oxide release. Am J Hypertens 1997;10:662-670.
137. [137] Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodelling in TGR(mREN2)27 transgenic rats. Circulation 1996;94:785-791.
138. [138] Müller DN, Hilgers KF, Bohlender J, et al. Effects of human renin in the vasculature of rats transgenic for human angiotensinogen. Hypertension 1995;26:272-278.
139. [139] Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994;94:978-984.
140. [140] Kawaguchi H, Shin WS, Wang Y, et al. In vivo gene transfection of human endothelial cell nitric oxide synthase in cardiomyocytes causes apoptosis-like cell death. Identification using Sendai virus-coated liposomes. Circulation 1997;95:2441-2447.
141. [141] Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich ED. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol 1979;237:H461-H468.
142. [142] Bing OHL, Brooks WW, Robinson KG, et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 1995;27:383-396.
143. [143] Li Z, Binh OH, Long X, Robinson KG, Lakatta EG. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997;272:H2312-H2319.
144. [144] Khadour FH, Kao RH, Park S, Armstrong PW, Holycross BJ, Schulz R. Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure. Am J Physiol 1997;273:H1223-H1230.
145. [145] Rubin Z, Miller JE, Rohrbacher E, Walsh GM. A potential model for human disease: spontaneous cardiomyopathy-congestive heart failure in SHR/N-cp rats. Human Pathol 1984;15:901-902.
146. [146] McCune SA, Baker PB, Stills HF. SHHF/Mcc-cp rat: model of obesity, noninsulin-dependent diabetes, and congestive heart failure. ILAR News 1990;32:23-27.
147. cp rats. J Cardiovasc Pharmacol 1997;29:726-733.
148. [148] Hohl CM, Hu B, Fertel RH, Russell JC, McCune SA, Altschuld RA. Effects of obesity and hypertension on ventricular myocytes: comparison of cells from adult SHHF/Mcc-cp and JCR:LA-cp rats. Cardiovasc Res 1993;27:238-242.
149. [149] Haas GJ, McCune SA, Brown DM, Cody RJ. Echocardiographic characterization of left ventricular adaptation in a genetically determined heart failure rat model. Am Heart J 1995;130:806-811.
150. [150] Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94:2837-2842.
151. [151] Sanders PW. Salt-sensitive hypertension: lessons from animal models. Am J Kid Dis 1996;28:775-782.
152. [152] Dahl LK, Knudsen KD, Ohanian EV, Muirhead M, Tuthill R. Role of gonads in hypertension prone rats. J Exp Med 1975;142:748-759.
153. [153] Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated left ventricles in Dahl salt-sensitive rats. Am J Physiol 1994;267:H2471-2482.
154. [154] He H, Kimura S, Fujisawa Y, et al. Dietary L-arginine supplementation normalizes regional blood flow in Dahl-Iwai salt-sensitive rats. Am J Hypertens 1997;10:89S-93S.
155. [155] Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-512.
156. [156] Zimmer H-G, Gerdes AM, Lortet S, Mall G. Changes in heart function and cardiac cell size in rats with chronic myocardial function. J Mol Cell Cardiol 1990;22:1231-1243.
157. [157] Stuver TP, Cove CJ, Hood WB. Mechanical abnormalities in the rat ischemic heart failure model which lie downstream to cAMP production. J Mol Cell Cardiol 1994;26:1221-1226.
158. [158] Bralet J, Marie C, Mossat C, Lecomte J-M, Gros C, Schwartz J-C. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin 1-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J Pharmacol Exp Ther 1994;270:8-14.
159. [159] Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74:86-90.
160. [160] Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol 1997;272:H722-H727.
161. [161] Capasso JM. Nisoldipine improves ventricular function in rats with ischemic heart failure. J Mol Cell Cardiol 1995;27:1841-1849.
162. [162] Capasso JM, Malhotra A, Li P, Zhang X, Scheuer J, Anversa P. Chronic nonocclusive coronary artery constriction impairs ventricular function, myocardial structure, and cardiac contractile protein enzyme activity in rats. Circ Res 1992;70:148-162.
163. [163] Medvedev OS, Gorodetskaya EA. Systemic and regional hemodynamic effects of perindopril in experimental heart failure. Am Heart J 1993;126:764-769.
164. [164] Lefrak EA, Pitha J, Rosenheim S, Gottlier JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-307.
165. [165] Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977;37:2705-2713.
166. [166] Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation of phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Int Med 1978;88:168-172.
167. [167] de Wildt DJ, de Jong Y, Hillen FC, Steerenberg PA, van Hoesel QGCM. Cardiovascular effects of doxorubicin-induced toxicity in intact Lou/M wsl rat and in isolated heart preparations. J Pharmacol Exp Ther 1985;235:234-240.
168. [168] Weinberg LH, Singal PK. Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rat. Can J Physiol Pharmacol 1987;65:1957-1965.
169. [169] Wakasurgi S, Wada A, Hasegawa Y, Nakano S, Shibata N. Detection of abnormal cardiac neurone activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 1992;33:208-214.
170. [170] Ambler GR, Johnston BM, Maxwell L, Gavin JB, Gluckman PD. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor 1. Cardiovasc Res 1993;27:1368-1373.
171. [171] Rubin E. Alcoholic myopathy in heart and skeletal muscle. New Engl J Med 1979;301:28-33.
172. [172] Capasso JM, Li R, Guideri G, Anversa P. Left ventricular dysfunction induced by chronic alcohol ingestion in rats. Am J Physiol 1991;261:H212-H219.
173. [173] Segel LD. Alcoholic cardiomyopathy in rats: inotropic responses to phenylephrine, glucagon, ouabain, and dobutamine. J Mol Cell Cardiol 1987;19:1061-1072.
174. [174] Strasser RH, Nuchter I, Rauch B, Marquetant R, Seitz H. Changes in cardiac signal transduction systems in chronic ethanol treatment preceding the development of alcoholic cardiomyopathy. Herz 1996;21:232-240.
175. [175] Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopath 1990;57:250-262.
176. [176] Koyama S, Kodama M, Izumi T, Shibata A. Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis. Cardiovasc Drugs Ther 1995;9:701-707.
177. [177] Okura Y, Yamamoto T, Goto S, et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 1997;29:491-502.
178. [178] Ishiyama S, Hiroe M, Nishikawa T, et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 1997;95:489-496.
179. [179] Zhang S, Kodama M, Hanawa H, Izumi T, Shibata A, Masani F. Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993;21:1254-1260.
180. [180] Junqueira Jr. LF, Beraldo PSS, Chapadeiro E, Jesus PC. Cardiac autonomic dysfunction and neuroganglionitis in a rat model of chronic Chaga's disease. Cardiovasc Res 1992;26:324-329.
181. [181] Meyrick B, Gamble W, Reid L. Development of Crotalaria hypertension: hemodynamic and structural study. Am J Physiol 1980;239:H692-H702.
182. [182] Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol 1981;240:H149-H155.
183. [183] Brown L, Lorenz B, Erdmann E. Reduced positive inotropic effects in diseased human myocardium. Cardiovasc Res 1986;20:516-520.
184. [184] Hilliker KS, Bell TG, Roth RA. Pneumotoxicity and thrombocytopenia after single injection of monocrotaline. Am J Physiol 1982;242:H573-H579.
185. [185] Hutchins GM, Anaya OA. Measurements of cardiac size, chamber volumes and valve orifices at autopsy. Johns Hopkins Med J 1973;133:96-106.
186. [186] Flaim SF, Minteer WJ, Nellis SH, Clark DP. Chronic arteriovenous shunt: evaluation of a model of heart failure. Am J Physiol 1979;236:H698-H704.
187. [187] Liu Z, Hilbelink DR, Crockett WB, Gerdes AM. Regional changes in hemodynamics and cardiac myocyte size in rats with aortacaval fistulas. 1. Developing and established hypertrophy. Circ Res 1991;69:52-58.
188. [188] Liu Z, Hilbelink DR, Gerdes AM. Regional changes in hemodynamics and cardiac myocyte size in rats with aortacaval fistulas. 2. Long-term effects. Circ Res 1991;69:59-65.
189. [189] Garcia R, Diebold S. Simple, rapid, and effective method of producing aortacaval shunts in the rat. Cardiovasc Res 1990;24:430-432.
190. [190] Arnal J-F, Philippe M, Laboulandine I, Mitchel J-B. Effects of perindopril in rat cardiac volume overload. Am Heart J 1993;126:776-782.
191. [191] Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995;92:3105-3112.
192. [192] Gerdes AM, Clark LC, Capasso JM. Regression of cardiac hypertrophy after closing an aortacaval fistula in rats. Am J Physiol 1995;268:H2345-H2351.
193. [193] Willenbrock R, Scheuermann M, Hohmel K, Luft FC, Dietz R. Acute and chronic neutral endopeptidase inhibition in rats with aortacaval shunt. Hypertension 1996;27:1259-1266.
194. [194] Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 1995;21:2642-2654.